AXSM

Axsome Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 6/10
  • Value↓ 0/10
Axsome Therapeutics sales and earnings growth
AXSM Growth
Good
  • Revenue Y/Y↑ 56.23%
  • EPS Y/Y↑ 35.53%
  • FCF Y/Y↑ 40.26%
Axsome Therapeutics gross and profit margin trends
AXSM Profitability
Neutral
  • Gross margin ↑ 92.60%
  • EPS margin↓ -26.60%
  • ROIC 5Y↓ -146.62%
Axsome Therapeutics net debt vs free cash flow
AXSM Risk
Great
  • Debt / Equity↑ 4.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -34.6

Axsome Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks